Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of polymyxin B for carbapenem-resistant gram-negative bacilli infection
ChiCTR1900026458Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Oct 2018
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of polymyxin B in Carbapenem-resistant Gram-negative bacterial infection (CRGNB), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoints: 28-day mortality, Duration of mechanical ventilation and 17 more. Started Oct 2018; status: recruiting.
02
Drugs
polymyxin B
03
Conditions
Carbapenem-resistant Gram-negative bacterial infection (CRGNB)
Beyond the preview
Go deeper on ChiCTR1900026458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026458.